ES2180629T3 - Usos terapeuticos de productos dimeros de proteina bactericida/aumentadora de la permeabilidad. - Google Patents

Usos terapeuticos de productos dimeros de proteina bactericida/aumentadora de la permeabilidad.

Info

Publication number
ES2180629T3
ES2180629T3 ES95913668T ES95913668T ES2180629T3 ES 2180629 T3 ES2180629 T3 ES 2180629T3 ES 95913668 T ES95913668 T ES 95913668T ES 95913668 T ES95913668 T ES 95913668T ES 2180629 T3 ES2180629 T3 ES 2180629T3
Authority
ES
Spain
Prior art keywords
protein
bactericide
therapeutic uses
protein products
permeability increased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913668T
Other languages
English (en)
Inventor
William Steve Ammons
Roger G Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Technology Ltd USA
Original Assignee
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd USA filed Critical Xoma Technology Ltd USA
Application granted granted Critical
Publication of ES2180629T3 publication Critical patent/ES2180629T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

COMPOSICIONES TERAPEUTICAS MEJORADAS, METODOS Y USOS DE PRODUCTOS DE PROTEINAS BACTERICIDAS O QUE AUMENTAN LA PERMEABILIDAD (BPI) QUE CONLLEVAN EL USO DE FORMAS DIMERICAS DE PRODUCTOS MONOMERICOS DE PROTEINAS (BPI) CARACTERIZADOS POR UNA ACTIVIDAD BIOLOGICA IN VIVO MEJORADA. LAS FORMULACIONES PREFERENTES INCLUYEN 50% O MAS, POR PESO, DEL PRODUCTO DIMERICO Y LOS USOS TERAPEUTICOS PREFERENTES INCLUYEN LA NEUTRALIZACION DE HEPARINA Y DE ENDOTOXINAS.
ES95913668T 1994-03-11 1995-03-13 Usos terapeuticos de productos dimeros de proteina bactericida/aumentadora de la permeabilidad. Expired - Lifetime ES2180629T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/212,132 US5447913A (en) 1994-03-11 1994-03-11 Therapeutic uses of bactericidal/permeability-increasing protein dimer products

Publications (1)

Publication Number Publication Date
ES2180629T3 true ES2180629T3 (es) 2003-02-16

Family

ID=22789691

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913668T Expired - Lifetime ES2180629T3 (es) 1994-03-11 1995-03-13 Usos terapeuticos de productos dimeros de proteina bactericida/aumentadora de la permeabilidad.

Country Status (11)

Country Link
US (4) US5447913A (es)
EP (1) EP0749317B1 (es)
JP (1) JPH09510217A (es)
AT (1) ATE218879T1 (es)
AU (1) AU703134B2 (es)
CA (1) CA2185155C (es)
DE (1) DE69527049T2 (es)
DK (1) DK0749317T3 (es)
ES (1) ES2180629T3 (es)
PT (1) PT749317E (es)
WO (1) WO1995024209A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1995019179A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-fungal methods and materials
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
CA2235626C (en) * 1995-11-14 2002-01-01 Xoma Corporation Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
AU735058B2 (en) 1996-05-10 2001-06-28 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
ATE234111T1 (de) * 1996-05-23 2003-03-15 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
CA2255865C (en) * 1996-05-24 2008-10-14 The Regents Of The University Of Minnesota Synthesis of soluble beta-sheet forming peptides
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
EP1304118A3 (en) * 1996-11-01 2004-01-14 XOMA Technology Ltd. Therapeutic uses and formulations for BPI protein products.
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US20050159343A1 (en) * 1999-03-26 2005-07-21 Board Of Regents, University Of Texas System Inhibitors of glycosaminoglycans
AU4204200A (en) * 1999-07-12 2001-01-30 Xoma Technology Ltd. Therapeutic uses of bpi protein products for inhibiting H+/K+ atpase activity
DE60116733T2 (de) * 2000-01-20 2006-11-02 Regents Of The University Of Minnesota, Minneapolis Peptide mit antibakterieller wirkung
US6686180B2 (en) * 2000-04-04 2004-02-03 Baxter International Inc. Method for the production of bacterial toxins
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Ｂｐｉタンパク質産物またはｂｐｉインヒビターを使用する、周皮細胞増殖の調節
US7056514B2 (en) 2002-02-20 2006-06-06 Regents Of The University Of Minnesota Partial peptide mimetics and methods
ATE496134T1 (de) 2002-03-29 2011-02-15 Xoma Technology Ltd Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
MX2011000862A (es) * 2008-07-21 2011-03-15 Otonomy Inc Composiciones antimicrobianas de liberacion controlada y metodos para el tratamiento de trastornos oticos.
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
CN117686438B (zh) * 2024-02-02 2024-05-10 东北大学秦皇岛分校 一种基于红外偏振光的远程材料鉴别方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US5439807A (en) * 1992-05-19 1995-08-08 Xoma Corporation Methods for the preparation of endotoxin-binding proteins
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
DK0690872T3 (da) * 1993-03-12 1999-05-10 Xoma Corp Biologisk aktive peptider fra funktionelle domæner af baktericidt/permeabilitetsforøgende protein og anvendelser deraf
CA2157927C (en) * 1993-03-12 1999-03-30 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein produc ts
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
ES2119185T3 (es) * 1993-03-12 1998-10-01 Xoma Corp Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
AU7330994A (en) * 1993-07-14 1995-02-13 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
DK0759774T3 (da) * 1993-09-22 2002-10-07 Xoma Technology Ltd Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
ZA947783B (en) * 1993-10-15 1996-05-05 Xoma Corp Method of treating depressed reticuloendothelial system function
CA2181164C (en) * 1994-01-14 2008-01-08 Arnold Horwitz Anti-gram-positive bacterial methods and materials
WO1995019179A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-fungal methods and materials
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries

Also Published As

Publication number Publication date
JPH09510217A (ja) 1997-10-14
CA2185155A1 (en) 1995-09-14
ATE218879T1 (de) 2002-06-15
EP0749317B1 (en) 2002-06-12
DE69527049D1 (de) 2002-07-18
US5703038A (en) 1997-12-30
DK0749317T3 (da) 2002-10-07
AU1996995A (en) 1995-09-25
WO1995024209A1 (en) 1995-09-14
US5447913A (en) 1995-09-05
PT749317E (pt) 2002-11-29
US5856302A (en) 1999-01-05
US6277821B1 (en) 2001-08-21
DE69527049T2 (de) 2003-03-06
CA2185155C (en) 2001-08-14
EP0749317A1 (en) 1996-12-27
AU703134B2 (en) 1999-03-18
HK1014159A1 (en) 1999-09-24

Similar Documents

Publication Publication Date Title
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
EE9400356A (et) Polüetüleenglükool proteiin konjugaadid, ühendid, nende kasutamine, meetod konjugaatide valmistamiseks ja ravimvormid
ATE186212T1 (de) Geschmacksmaskierte pharmazeutische mittel
ES2054038T3 (es) Esteres y tioesteres aromaticos, su procedimiento de preparacion y su utilizacion en medicina humana o veterinaria y en cosmetica.
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
FR13C0021I2 (fr) Conjugates d'exendin-4 et leur utilisation medicale
HU214593B (hu) Kozmetikai, higiéniai, valamint szépség- és testápoló készítmények és eljárás azok előállítására
SE9804614D0 (sv) New peptides and use thereof
RU95106680A (ru) Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции
TR200100637T2 (tr) Yeni doğal ürün türevleri
ES2184901T3 (es) Anticuerpos anti-idiotipicos del factor de crecimiento endotelial vascular y su utilizacion como medicamentos.
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
TR199700963T1 (xx) Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.
AU4872797A (en) Novel biaromatic dibenzofuran derivatives and their use in human or veterinary medicine and in cosmetics
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
IT216694Z2 (it) Manopola monouso, per l'igiene personale di pazienti in genere.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
ATE134865T1 (de) Haarpflegemittel
DE69323191D1 (de) Wasserlösliche retinoide
ES2176955T3 (es) Productos cosmeticos o dermo-farmaceuticos que respetan la ecologia cutanea.
CA2214675A1 (en) Methods and compositions for sedating, anaesthetising and euthanising aquatic organisms
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
ITCB950001A0 (it) Deamarizzazione delle olive da tavola per via microbiologica, mediantel'impiego di microorganismi oleuropeinolitici selezionati
ZA925784B (en) Polypeptides capable of inducing antibodies in vivo themselves capable of inhibiting the invasion of red blood cells by merozoites of P. falciparum, related products and their use in the production of vaccine compositions.